Ionis Pharmaceuticals, Inc. (IONS) Pops to All Time High

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Corporate Logo

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) having $76.99 price per share and $81.61 target hit all time high on Mar, 14. The all time high was published by Barchart.com. The company has $10.66 billion MC. The valuation of NASDAQ:IONS can change by $639.30 million if our $81.61 target is hit.

IONS is reaching $76.99 during the last trading session, after increased 0.50%.Currently Ionis Pharmaceuticals, Inc. is uptrending after 33.45% change in last March 14, 2018. IONS has 510,692 shares volume. IONS outperformed the S&P 500 by 29.08%.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)’s quarterly earnings will be reported on May, 3., according to Zacks. Analysts predict $0.23 EPS, which is $0.24 up or 2,400.00 % from 2018’s $-0.01 EPS. IONS’s profit could reach $31.83M with 83.68 P/E in case $0.23 EPS is reported. After $2.35 EPS report previous quarter, Wall Street now forecasts -90.21 % negative EPS growth of Ionis Pharmaceuticals, Inc..

For more Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) news released briefly go to: Seekingalpha.com, Nasdaq.com, Investorplace.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Ionis Pharmaceuticals Q4 Earnings Preview – Seeking Alpha” released on February 26, 2019, “Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for – Nasdaq” on February 20, 2019, “6 of the Most Expensive Stocks That Could Go On Sale – Investorplace.com” with a publish date: March 08, 2019, “Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen) – Nasdaq” and the last “Ionis Pharmaceuticals Funds Its Pipeline of More Than 40 Drugs – Nasdaq” with publication date: March 04, 2019.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics.The company has $10.66 billion market cap. The firm markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and as an adjunct to lipid lowering medications and diet.The P/E ratio is 37.19. The Company’s drugs in Phase III development include volanesorsen for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug for transthyretin amyloidosis.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.